Background
- Papillary thyroid cancer (PTC) usually carries a good prognosis after surgery +/- radioactive iodine therapy (RAI).
- 5-15% of patients become RAI refractory, and some require systemic therapy.
- BRAF-V600E, the most common mutation in PTC, is associated with poor outcomes.
- The effectiveness of TKI compared to BRAF-targeted therapy (BRAF/MEKi) and immunotherapy (IO) remains unclear in the BRAF-V600E mutant (BRAF-m) population.